



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Report for the Application PartII with MSC: Czechia

A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK-3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007).

2023-505712-37-00

MSC: Czechia

Site: Vseobecná Fakultní Nemocnice V Praze

Department name:

Dermatovenerologická klinika

Site Street Address:

U Nemocnice 499/2

Site City:

Prague

Site Post Code:

128 00

Site Country:

Czechia

First Name:

Ivana

Last Name:

Krajsova

Title:**Telephone number:**

+420224962426

Email:

ivana.krajsova@vfn.cz

Site: Fakultni Nemocnice Kralovske Vinohrady

Department name:

Dermatovenerologicka klinika

Site Street Address:

Srobarova 1150/50

Site City:

Prague 10

Site Post Code:

100 00

Site Country:

Czechia

First Name:

Petr

Last Name:

Arenberger

Title:**Telephone number:**

+420267162340

Email:

avemedica@email.cz